Anlotinib plus TQB2450 (PD-L1 blockade) combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer: A single-arm, open-label phase II clinical trial

被引：0
|
作者：
Jin, Shui-Ling
Qiao, Shishi
Li, Ren-Feng
Zhang, Weijie
He, Wei
Su, Chang
Li, Lu-Hao
Pan, Jie
Guo, Wen-Zhi
Zong, Hong
机构：
[1] Zhengzhou Univ, Affiliated Hosp 1, Dept Med Oncol, Zhengzhou, Peoples R China
[2] Zhengzhou Univ, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.3_suppl.498
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：498 / 498
页数：1
相关论文
共 50 条
  • [41] Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for advanced esophageal squamous cell carcinoma (ESCC): A multicenter, single-arm, open-label phase II clinical trial.
    Wang Junsheng
    Luo Suxia
    Li Ning
    Wu Tao
    Hong Yonggui
    Guo Yanzhen
    Cheng Yufeng
    Li Baosheng
    Tan Bingxu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [42] Multicenter phase I/II trial of gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer
    Pressiani, Tiziana
    Balsano, Rita
    Giordano, Laura
    Milella, Michele
    Bergamo, Francesca
    Bozzarelli, Silvia
    Noventa, Silvia
    Ferrrari, Daris
    Scartozzi, Mario
    Parra, Hector Soto
    Auriemma, Alessandra
    Solda, Caterina
    Zaniboni, Alberto
    Zecchetto, Camilla
    Rizzato, Mario Domenico
    Rimassa, Lorenza
    Santoro, Armando
    EUROPEAN JOURNAL OF CANCER, 2024, 207
  • [43] Anlotinib in combined with anti-PD-L1 antibody Benmelstobart(TQB2450) versus sunitinib in first-line treatment of advanced renal cell carcinoma (RCC): A randomized, open-label, phase III study (ETER100)
    Sheng, X.
    Shen, P.
    Qu, W.
    Wang, Z.
    Li, Y.
    Ren, X.
    Jiang, S.
    Li, G.
    Fu, C.
    Qin, W.
    Wu, J.
    Chen, P.
    Guo, H.
    Zhou, F.
    Ji, Z.
    Yang, A.
    Chen, K.
    Li, L.
    Zhou, A.
    Guo, J.
    ANNALS OF ONCOLOGY, 2024, 35 : 1263 - 1264
  • [44] Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial
    Wei, W.
    Ban, X.
    Yang, F.
    Huang, Y.
    Li, J.
    Cheng, X.
    Zheng, M.
    Li, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S762 - S762
  • [45] Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase 2 study.
    Du, Juan
    Tong, Fan
    Sha, Hui-zi
    Sun, Yi
    Zhu, Yahui
    Qi, Liang
    Li, Xiaoqin
    Li, Wei
    Yang, Yan
    Li, Zeqing
    Xu, Caihua
    Ni, Jiayao
    Gu, Qing
    Zhang, Xing
    Zhu, Chan
    Wang, Xiaoxuan
    Liu, Baorui
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] A multi-center, open-label, randomized controlled trial of nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine for first-line treatment of advanced pancreatic cancer (PC)
    Jin, M.
    Liu, H.
    Lin, Z.
    Xue, J.
    Liu, J.
    Bao, L.
    Luo, Z.
    Yu, X.
    Li, S.
    Hu, J.
    Zhang, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S311 - S311
  • [47] Gemcitabine plus Nab-paclitaxel as a second-line treatment for patients with advanced pancreatic cancer after FOLFIRINOX failure: a multicenter, single-arm, open-label, phase 2 trial
    Choi, Jin Ho
    Lee, Hee Seung
    Huh, Gunn
    Lee, Sang Hyub
    Paik, Woo Hyun
    Ryu, Ji Kon
    Kim, Yong-Tae
    Bang, Seungmin
    Lee, Eaum Seok
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 122 - 122
  • [48] TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer
    D. Ferraro
    D. Goldstein
    R. L. O’Connell
    J. R. Zalcberg
    K. M. Sjoquist
    N. C. Tebbutt
    P. Grimison
    S. McLachlan
    L. L. Lipton
    P. Vasey
    V. J. Gebski
    C. Aiken
    M. Cronk
    S. Ng
    C. S. Karapetis
    J. Shannon
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 361 - 367
  • [49] TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer
    Ferraro, D.
    Goldstein, D.
    O'Connell, R. L.
    Zalcberg, J. R.
    Sjoquist, K. M.
    Tebbutt, N. C.
    Grimison, P.
    McLachlan, S.
    Lipton, L. L.
    Vasey, P.
    Gebski, V. J.
    Aiken, C.
    Cronk, M.
    Ng, S.
    Karapetis, C. S.
    Shannon, J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) : 361 - 367
  • [50] Fruquinitinib combined with nab-paclitaxel and gemcitabine (AG) as the first-line treatment for pancreatic ductal adenocarcinoma (PDAC) with liver metastases: An open-label, single-arm, single-center phase II clinical study
    Wei, M.
    Shi, S.
    Li, J.
    Du, N.
    Yu, X.
    Xu, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S933 - S933
12345